Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2011-04, Vol.67 (4), p.967-969
Hauptverfasser:	Helbig, Grzegorz, Moskwa, Andrzej, Hus, Marek, Piszcz, Jarosław, Swiderska, Alina, Urbanowicz, Alina, Całbecka, Małgorzata, Seferyńska, Ilona, Raźny, Małgorzata, Rodzaj, Marek, Żuk, Ewa, Kyrcz-Krzemień, Sławomira
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Benzamides Cancer Cancer Research Chronic Disease Dose-Response Relationship, Drug Female Follow-Up Studies Humans Hypereosinophilic Syndrome - drug therapy Hypereosinophilic Syndrome - pathology Imatinib Mesylate Letter to the Editor Life Sciences Male Medicine Medicine & Public Health Middle Aged mRNA Cleavage and Polyadenylation Factors - genetics Oncogene Proteins, Fusion - genetics Oncology Pharmacology/Toxicology Piperazines - administration & dosage Piperazines - pharmacokinetics Piperazines - therapeutic use Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Receptor, Platelet-Derived Growth Factor alpha - genetics Remission Induction - methods Retrospective Studies Splenomegaly - etiology Time Factors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!